S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY

• Matthew Heeney1,
• David Rees,
• Mariane de Montalembert,
• Isaac Odame,
• Yasser Wali,
• Sarfaraz Sayyed,
• Velusamy Shanmuganathan Muthusamy,
• Anisha E. Mendonza,
• Michele Nassin,
• Deborah Keefe,
• Julie Kanter

Affiliations

Matthew Heeney1

1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, United States

David Rees

2 King’s College Hospital, Department of Paediatric Haematology, London, United Kingdom

Mariane de Montalembert

3 Hôpital Universitaire Necker-Enfants Malades, Paris, France

Isaac Odame

4 The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, Canada

Yasser Wali

5 Sultan Qaboos University, Child Health Department, Muscat, Oman

Sarfaraz Sayyed

6 Novartis Healthcare Pvt. Ltd., Hyderabad, India

Velusamy Shanmuganathan Muthusamy

6 Novartis Healthcare Pvt. Ltd., Hyderabad, India

Anisha E. Mendonza

7 Novartis Institutes for BioMedical Research, Cambridge, United States

Michele Nassin

8 Novartis Pharmaceuticals Corporation,, East Hanover, United States

Deborah Keefe

8 Novartis Pharmaceuticals Corporation,, East Hanover, United States

Julie Kanter

9 University of Alabama-Birmingham, Division of Hematology-Oncology, Birmingham, United States